Nephrology · Fremont, CA
NPI
1962440263
Since 2006
Specialty
Nephrology
Code 174400000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
39233 Liberty St
Fremont, CA, 94538
Phone (510) 795-8186
Groups this clinician bills Medicare through
Medicare paid, 2024
$434K
2,729 services
Medicare patients, 2024
448
Average age 77
Drug cost, 2024
$925K
2,677 prescriptions
Company payments, 2025
$668
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David Tay was code 99232 (hospital e&m - subsequent), 734 times for 160 patients. In total David Tay billed 2,729 services in 22 codes, and Medicare paid $434K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-05-18.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 734 | 160 | $75.00 | $55K |
| 90960 ESRD Related Services (not dialysis) | Office | 675 | 73 | $342.66 | $231K |
| 99214 Office E&M - Established | Office | 422 | 210 | $113.88 | $48K |
| 90935 Hemodialysis | Facility | 245 | 61 | $67.46 | $17K |
| 99223 Hospital E&M - Initial | Facility | 200 | 125 | $164.87 | $33K |
| 99213 Office E&M - Established | Office | 65 | 52 | $68.80 | $4,472 |
| 99233 Hospital E&M - Subsequent | Facility | 60 | 44 | $113.35 | $6,801 |
| 90961 ESRD Related Services (not dialysis) | Office | 42 | 27 | $278.33 | $12K |
| 90937 Hemodialysis | Facility | 32 | 16 | $97.22 | $3,111 |
| 99215 Office E&M - Established | Facility | 22 | 19 | $139.23 | $3,063 |
| 99215 Office E&M - Established | Office | 22 | 15 | $154.57 | $3,400 |
| 99231 Hospital E&M - Subsequent | Facility | 22 | 18 | $44.69 | $983 |
| 99205 Office E&M - New | Office | 21 | 21 | $214.58 | $4,506 |
| 90962 ESRD Related Services (not dialysis) | Office | 18 | 11 | $191.55 | $3,448 |
| 99214 Office E&M - Established | Facility | 14 | 12 | $93.62 | $1,311 |
By year: 2022 $507K for 3,404 services; 2023 $479K for 3,536 services; 2024 $434K for 2,729 services.
Medicare prescription drug claims, 2024
In 2024, the drug David Tay prescribed most often to Medicare patients was Amlodipine Besylate, with 222 prescriptions and refills. In total David Tay wrote 2,677 Medicare prescriptions that cost $925K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Amlodipine Besylate Generic | 222 | 621 | 72 | $1,833 |
| Allopurinol Generic | 198 | 558 | 60 | $2,571 |
| Doxazosin Mesylate Generic | 179 | 456 | 51 | $3,119 |
| Calcitriol Generic | 155 | 437 | 41 | $4,163 |
| Farxiga Dapagliflozin Propanediol | 126 | 222 | 30 | $119K |
| Losartan Potassium Generic | 121 | 360 | 37 | $1,158 |
| Jardiance Empagliflozin | 117 | 303 | 33 | $163K |
| Lisinopril Generic | 113 | 326 | 35 | $481 |
| Bumetanide Generic | 97 | 284 | 35 | $4,750 |
| Sevelamer Carbonate Generic | 95 | 234 | 31 | $40K |
| Kerendia Finerenone | 81 | 197 | 22 | $120K |
| Carvedilol Generic | 66 | 179 | 20 | $794 |
| Procrit Epoetin Alfa | 65 | 82 | 12 | $51K |
| Tamsulosin Hcl Generic | 61 | 155 | 19 | $1,358 |
| Febuxostat Generic | 60 | 168 | 16 | $13K |
Brand drugs: 592 claims; generic drugs: 2,085 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David Tay $668 ($668 in general payments such as food, travel and fees) from 8 companies. The largest payer was Fresenius USA Marketing, Inc. with $262.
| Company | Payments | Amount |
|---|---|---|
| Fresenius USA Marketing, Inc. | 15 | $262 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 4 | $101 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $96.41 |
| Calliditas Therapeutics US Inc. | 2 | $50.04 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $49.3 |
| Amgen Inc. AMGN | 2 | $42.45 |
| Mallinckrodt Hospital Products Inc. | 1 | $33.85 |
| OPKO Pharmaceuticals, LLC | 2 | $33.15 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.